How Andelyn Biosciences is targeting GMP scale-up challenges in lentiviral vector manufacturing
Cell therapy needs lentiviral vectors, but GMP scale-up remains messy. Andelyn Biosciences is betting standardization can close that gap.
Pharma & Biotech
Pharma & Biotech
Kexing Biopharm leans on IQVIA as biosimilar competition moves from China to global markets
Biosimilars need speed, but regulators still demand proof. IQVIA and Kexing test whether AI can cut friction without cutting evidence.
Pharma & Biotech
Why Fosun Pharma’s AriBio deal could reshape the race for oral Alzheimer’s therapies
Alzheimer’s drugs are moving beyond antibodies. Fosun Pharma’s AR1001 option turns one Phase 3 readout into a global commercial test.
Pharma & Biotech
Why OnCusp Therapeutics’ CFO hire matters for its CDH6 antibody-drug conjugate strategy
CDH6 ADCs are heating up. OnCusp Therapeutics now needs capital discipline to turn CUSP06 promise into clinical and investor credibility.
Pharma & Biotech
Degron Therapeutics extends Series A as DEG6498 enters the harder phase of cancer drug validation
Molecular glue funding is back, but clinic data remain thin. Degron’s HuR bet now faces the proof burden in solid tumors.
Pharma & Biotech
Iterative Health deepens cardiovascular research footprint with NextStage Clinical Research site deal
Cardiology trials need faster, broader recruitment. Iterative Health’s Texas site deal tests whether community networks can close the gap.
Pharma & Biotech
Can Thermo Fisher help Nuvation Bio scale Ibtrozi supply for ROS1-positive NSCLC?
Rare cancer drugs need more than FDA approval. Nuvation Bio’s Ibtrozi test now shifts to U.S. supply reliability and launch execution.
Pharma & Biotech
Terumo BCT and Steminent push automation into the fragile world of stem cell manufacturing
MSC science is advancing faster than manufacturing can scale. Terumo BCT and Steminent are testing whether automation can close that gap.
Pharma & Biotech
Can payload-linker manufacturing help Piramal Pharma Solutions reset CDMO momentum?
ADC demand is rising, but manufacturing remains a bottleneck. Piramal Pharma Solutions is betting Riverview can narrow that gap.
Pharma & Biotech
What OrganaBio’s Excellos asset acquisition reveals about next-generation CDMO demand
Cell therapy needs redundancy, not just cleanrooms. OrganaBio’s Excellos deal tests whether bicoastal CDMO scale can reduce developer risk.